{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:43:39Z","timestamp":1753922619145,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Danube University Krems University for Continuing Education"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Botulinum toxin A (BoNT-A) is considered a safe and effective treatment for spasticity and dystonia. Individual interinjection intervals are critical for the maintenance of the effect. In Austria, BoNT outpatient clinics were shutdown from November to December 2020 during COVID-19 control measures, leading to rescheduling of BoNT-A injections. This survey aimed at investigating the influence of injection delays on symptoms, physical functioning, and quality of life (QoL) of the affected patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between April and July 2021, 32 outpatients (21 females, mean age: 63.4\u2009\u00b1\u200912.1\u00a0years) treated\u2009\u2265\u200912\u00a0months at the BoNT outpatient clinic Horn-Allentsteig (Austria) and experienced\u2009\u2265\u20092\u00a0week injection delays, completed a structured face-to-face questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Indications were dystonia (34%), spasticity (63%), and hyperhidrosis (3%). Injections were delayed by 10\u00a0weeks (median, range: 2\u201315). Muscle cramps increased in 95% of patients with spasticity, muscle twitches in 91% of those with dystonia, and pain in 9% and 60% for dystonia and spasticity, respectively. Overall, 75% reported functional worsening, and deterioration in QoL by 62.6%\u2009\u00b1\u200916.8 (mean\u2009\u00b1\u2009SD). The impact on QoL correlated with the subjective global improvement induced by BoNT-A (Rs: 0.625; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). For 75%, long-term assurance of BoNT-A therapy was very important, and 81% felt their patient rights not respected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>COVID-19-related delays in BoNT-A injections illustrate the importance of this therapy for symptom relief, functional outcome, and QoL in patients suffering from involuntary muscle hyperactivity. BoNT-A therapy is essential and has to be guaranteed even in circumstances such as the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00702-021-02430-z","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T18:02:41Z","timestamp":1635012161000},"page":"49-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-7943","authenticated-orcid":false,"given":"Yvonne","family":"Teuschl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bancher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-4962","authenticated-orcid":false,"given":"Michael","family":"Brainin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Dachenhausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2851-9897","authenticated-orcid":false,"given":"Karl","family":"Matz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-2954","authenticated-orcid":false,"given":"Michaela M.","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"2430_CR1","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/head.13830","volume":"60","author":"A Ali","year":"2020","unstructured":"Ali A (2020) Delay in Onabotulinumtoxin-A treatment during the COVID-19 pandemic-perspectives from a virus hotspot. Headache 60:1183\u20131186. https:\/\/doi.org\/10.1111\/head.13830","journal-title":"Headache"},{"key":"2430_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3389\/fneur.2020.00719","volume":"11","author":"A Baricich","year":"2020","unstructured":"Baricich A, Santamato A, Picelli A, Morone G, Smania N, Paolucci S, Fiore P (2020) Spasticity treatment during COVID-19 pandemic: clinical recommendations. Front Neurol 11:719. https:\/\/doi.org\/10.3389\/fneur.2020.00719","journal-title":"Front Neurol"},{"key":"2430_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00702-020-02235-6","volume":"127","author":"D Dressler","year":"2020","unstructured":"Dressler D, Adib Saberi F (2020) Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions from a German cohort. J Neural Transm 127:1271\u20131274. https:\/\/doi.org\/10.1007\/s00702-020-02235-6","journal-title":"J Neural Transm"},{"key":"2430_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00702-021-02312-4","volume":"128","author":"D Dressler","year":"2021","unstructured":"Dressler D, Altavista MC, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, Chung TM, Colosimo C, Fheodoroff K, Garcia-Ruiz PJ, Jeon B, Jin L, Kanovsky P, Milanov I, Micheli F, Orlova O, Pandey S, Pirtosek Z, Relja M, Rosales R, Sag\u00e1stegui-Rodr\u00edguez JA, Shahidi GA, Timerbaeva S, Wan X, Walter U, Saberi FA (2021) Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm 128:321\u2013335. https:\/\/doi.org\/10.1007\/s00702-021-02312-4","journal-title":"J Neural Transm"},{"key":"2430_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10072-020-04940-2","volume":"42","author":"R Erro","year":"2021","unstructured":"Erro R, Scannapieco S, Russo M, Picillo M, Barone P (2021) Impact of COVID-19 on neurological patients attending a botulinum toxin service. Neurol Sci 42:433\u2013435. https:\/\/doi.org\/10.1007\/s10072-020-04940-2","journal-title":"Neurol Sci"},{"key":"2430_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.576117","volume":"11","author":"A Esquenazi","year":"2020","unstructured":"Esquenazi A, Delgado MR, Hauser RA, Picaut P, Foster K, Lysandropoulos A, Gracies JM (2020) Duration of symptom relief between injections for Abobotulinumtoxin-A (Dysport\u00ae) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol 11:576117. https:\/\/doi.org\/10.3389\/fneur.2020.576117","journal-title":"Front Neurol"},{"key":"2430_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fneur.2020.00388","volume":"11","author":"J Jacinto","year":"2020","unstructured":"Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A (2020) Patient perspectives on the therapeutic profile of botulinum neurotoxin type-A in spasticity. Front Neurol 11:388. https:\/\/doi.org\/10.3389\/fneur.2020.00388","journal-title":"Front Neurol"},{"key":"2430_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.14802\/jmd.20088","volume":"14","author":"AT Pajo","year":"2021","unstructured":"Pajo AT, Espiritu AI, Jamora RDG (2021) Impact and challenges of the COVID-19 pandemic on patients requiring botulinum toxin A treatment. J Mov Disord 14:29\u201333. https:\/\/doi.org\/10.14802\/jmd.20088","journal-title":"J Mov Disord"},{"key":"2430_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14569","author":"E Ranza","year":"2020","unstructured":"Ranza E, Mammi P, Rampello A, Annamaria S, Brianti R (2020) Botulinum toxin therapy during the COVID-19 outbreak: experience of an Italian multidisciplinary team. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.14569","journal-title":"Eur J Neurol"},{"key":"2430_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/toxins10070253.","volume":"10","author":"RL Rosales","year":"2018","unstructured":"Rosales RL, Balcaitiene J, Berard H, Maisonobe P, Goh KJ, Kumthornthip W, Mazlan M, Latif LA, Delos Santos MMD, Chotiyarnwong C, Tanvijit P, Nuez O, Kong KH (2018) Early Abobotulinumtoxin-A (Dysport\u00ae) in post-stroke adult upper limb spasticity: ONTIME Pilot Study. Toxins 10:253. https:\/\/doi.org\/10.3390\/toxins10070253.","journal-title":"Toxins"},{"key":"2430_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/toxins13020101","volume":"13","author":"S Samadzadeh","year":"2021","unstructured":"Samadzadeh S, Brauns R, Rosenthal D, Hefter H (2021) The impact of SARS-CoV-2 pandemic lockdown on a botulinum toxin outpatient clinic in Germany. Toxins 13:101. https:\/\/doi.org\/10.3390\/toxins13020101","journal-title":"Toxins"},{"key":"2430_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.23736\/S1973-9087.20.06478-3","volume":"57","author":"A Santamato","year":"2021","unstructured":"Santamato A, Facciorusso S, Spina S, Cinone N, Avvantaggiato C, Santoro L, Ciritella C, Smania N, Picelli A, Gasperini G, Molteni F, Baricich A, Fiore P (2021) Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post-stroke and traumatic brain injury patients living with spasticity. Eur J Phys Rehabil Med 57:424\u2013433. https:\/\/doi.org\/10.23736\/S1973-9087.20.06478-3","journal-title":"Eur J Phys Rehabil Med"},{"key":"2430_CR13","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA (2016) Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:1818\u20131826. https:\/\/doi.org\/10.1212\/WNL.0000000000002560","journal-title":"Neurology"},{"key":"2430_CR14","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s10072-021-05282-3","volume":"42","author":"D Tarantino","year":"2021","unstructured":"Tarantino D, Gnasso R, Migliore F, Iommazzo I, Sirico F, Corrado B (2021) The effects of COVID-19 pandemic countermeasures on patients receiving botulinum toxin therapy and on their caregivers: a study from an Italian cohort. Neurol Sci 42:3071\u20133077. https:\/\/doi.org\/10.1007\/s10072-021-05282-3","journal-title":"Neurol Sci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-021-02430-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T14:07:42Z","timestamp":1641478062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-021-02430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2430"],"URL":"https:\/\/doi.org\/10.1007\/s00702-021-02430-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"type":"print","value":"0300-9564"},{"type":"electronic","value":"1435-1463"}],"subject":[],"published":{"date-parts":[[2021,10,23]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the local ethics committee of the Danube University Krems (NUMBER EK GZ 42\/2018-2021, March, 24, 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Verbal informed consent was obtained from all individual participants prior to the interview.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}